Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
BMC Infect Dis ; 22(1): 341, 2022 Apr 05.
Artigo em Inglês | MEDLINE | ID: mdl-35382770

RESUMO

BACKGROUND: Some tuberculosis (TB) treatment guidelines recommend daily TB treatment in both the intensive and continuation phases of treatment in HIV-positive persons to decrease the risk of relapse and acquired drug resistance. However, guidelines vary across countries, and treatment is given 7, 5, 3, or 2 days/week. The effect of TB treatment intermittency in the continuation phase on mortality in HIV-positive persons on antiretroviral therapy (ART), is not well-described. METHODS: We conducted an observational cohort study among HIV-positive adults treated for TB between 2000 and 2018 and after enrollment into the Caribbean, Central, and South America network for HIV epidemiology (CCASAnet; Brazil, Chile, Haiti, Honduras, Mexico and Peru). All received standard TB therapy (2-month initiation phase of daily isoniazid, rifampin or rifabutin, pyrazinamide ± ethambutol) and continuation phase of isoniazid and rifampin or rifabutin, administered concomitantly with ART. Known timing of ART and TB treatment were also inclusion criteria. Kaplan-Meier and Cox proportional hazards methods compared time to death between groups. Missing model covariates were imputed via multiple imputation. RESULTS: 2303 patients met inclusion criteria: 2003(87%) received TB treatment 5-7 days/week and 300(13%) 2-3 days/week in the continuation phase. Intermittency varied by site: 100% of patients from Brazil and Haiti received continuation phase treatment 5-7 days/week, followed by Honduras (91%), Peru (42%), Mexico (7%), and Chile (0%). The crude risk of death was lower among those receiving treatment 5-7 vs. 2-3 days/week (HR = 0.68; 95% CI = 0.51-0.91; P = 0.008). After adjusting for age, sex, CD4, ART use at TB diagnosis, site of TB disease (pulmonary vs. extrapulmonary), and year of TB diagnosis, mortality risk was lower, but not significantly, among those treated 5-7 days/week vs. 2-3 days/week (HR 0.75, 95%CI 0.55-1.01; P = 0.06). After also stratifying by study site, there was no longer a protective effect (HR 1.42, 95%CI 0.83-2.45; P = 0.20). CONCLUSIONS: TB treatment 5-7 days/week was associated with a marginally decreased risk of death compared to TB treatment 2-3 days/week in the continuation phase in multivariable, unstratified analyses. However, little variation in TB treatment intermittency within country meant the results could have been driven by other differences between study sites. Therefore, randomized trials are needed, especially in heterogenous regions such as Latin America.


Assuntos
Infecções por HIV , Tuberculose , Adulto , Antituberculosos/uso terapêutico , Brasil , Estudos de Coortes , Infecções por HIV/epidemiologia , Humanos , Isoniazida/uso terapêutico , Tuberculose/complicações , Tuberculose/tratamento farmacológico
2.
Rev. fac. cienc. méd. (Impr.) ; 9(1)ene.-jun. 2012.
Artigo em Espanhol | LILACS | ID: lil-699538

RESUMO

En general la prevalencia de depresión a nivel mundial es del 15%, en América Latina varía de 4.5-7.1%. En Honduras el tema no ha sido suficientemente estudiado. Objetivo. Determinar la prevalencia de la depresión mayor y algunos factores relacionados en mujeres mayores de 18 años, con el propósito de proponer recomendaciones a la Secretaria de Salud para un diagnóstico oportuno y un manejo adecuado. Material y Métodos; estudio tipo, descriptivo en dos fases: trasversal y prospectivo longitudinal. Muestra 228 mujeres mayores de 18 años, muestreo: aleatorio simple. La recolección de los datos se ejecutó a través de un instrumento tipo encuesta estructurado que incluía los datos generales del entrevistado, y el Cuestionario Sobre la Salud del Paciente(PHQ9) para detectar depresión. A las personas diagnosticadas con depresión mayor se les administró tratamiento farmacológico antidepresivo o fue referido a otro nivel. Se evaluó la respuesta terapéutica a las 6 y 12 semanas de iniciado el tratamiento. Se diseñó una base de datos en Epi-Info 3.5, se aplicaron pruebas descriptivas Resultados: Se encontró una prevalencia de 6.1%, de éstas: 50% tenían 50 años o más, 64.3% analfabetas, 57.1% solteras, 64.2% tenían 2 ó más hijos, 50% sufre alguna patología. Se les indicó tratamiento antidepresivo; a las 6 semanas el 42.9% tomaron su medicamento, 57.1% no lo hizo porque no acudieron al Hospital con la referencia proporcionada. A las 12 semanas el 14.3% tomó su medicamento, 28.6% no lo tomó, refiriendo sentirse mejor. Conclusiones: La prevalencia de depresión mayor fue de 6.1% y los factores de riesgo fueron: ser mujer mayor de 40 años de edad, ser analfabeta, tener antecedentes de comportamiento violento en la familia, tener regulares o malas relaciones familiares y poseer antecedentes personales patológicos...


Assuntos
Feminino , Transtorno Depressivo Maior , Depressão/diagnóstico , Transtornos do Humor/classificação , Ansiedade/psicologia , Atenção Primária à Saúde/estatística & dados numéricos
5.
Med. clín. (Honduras) ; 2(3/4): 47-54, jul.-dic. 1993. tab
Artigo em Espanhol | LILACS | ID: lil-139858

RESUMO

El presente trabajo es un análisis de los resultados de los estudios de sensibilidad de las bacterias aisladas de distintas muestras clinicas, a los antibioticos, en el Hospital Escuela en el año 1993, se hacen comparaciones de estos datos con estudios similares de años anteriores y recomendaciones para futuros estudios


Assuntos
Resistência Microbiana a Medicamentos , Antibacterianos , Hospitais Estaduais , Testes de Sensibilidade Microbiana/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...